TOP1 Priority: Advancing Biomarker-Driven Patient Selection for the Use of ADCs.
editorial · Level V
Where this comes from
- Record sourced from PubMed, PMID 40095530.
- Also identified by DOI 10.1158/1078-0432.CCR-25-0166.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
A recent study reports the emergence of TOP1 mutations as a potential mechanism of resistance to topoisomerase inhibitor antibody-drug conjugates (ADC) in advanced breast cancer. This is a crucial first step in identifying biomarkers to guide ADC therapy selection and underscores the need for caution when sequencing ADCs with similar payloads. See related article by Abelman et al., p. 1966.
Medical subject headings
- Biomarkers, Tumor
- Immunoconjugates
- DNA Topoisomerases, Type I
- Topoisomerase I Inhibitors
- Breast Neoplasms
- Neoplasms